Defence Therapeu Stock Price, News & Analysis

Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has appointed Dr. Amie Phinney, PhD, MBA to its Board of Directors. Dr. Phinney, who recently joined as Strategy and Business Advisor, will now expand her role to help drive governance and long-term value creation.

The company has granted Dr. Phinney 100,000 stock options, exercisable at $0.75 per share for three years, vesting immediately. This appointment strengthens Defence's leadership team as it advances its drug-delivery platform development.

Defence Therapeutics (OTCQB: DTCFF) has successfully completed a non-brokered private placement of debenture units, raising $2 million in gross proceeds. Each unit, priced at $1,000, comprises an 8.0% convertible debenture maturing September 15, 2027, and 1,666 common share purchase warrants.

The debentures are convertible into common shares at $0.60 per share, while warrants are exercisable at $0.75 per share. The company paid $160,000 in finder's fees and issued 266,667 finder's warrants. The proceeds will be used to advance Defence's science programs and for working capital.

Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has appointed Dr. Amie Phinney as Strategy & Business Advisor. Dr. Phinney brings over 20 years of experience in pharmaceutical R&D and biotech innovation, having held key positions at Abbott, AbbVie, and Solvay Pharmaceuticals.

Dr. Phinney's extensive background includes serving as Chief Scientific Officer at Lakeside Discovery and Senior Director of Partnerships at adMare BioInnovations. She holds a PhD in Biomedical Research and an MBA, with additional executive training from prestigious institutions. The appointment aims to help Defence Therapeutics capitalize on new opportunities emerging from recent scientific advances in antibody-delivered therapeutics.

Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has announced a non-brokered private placement of debenture units. The company aims to raise up to $1.2 million through the offering of units priced at $1,000 each.

Each unit comprises an 8.0% convertible debenture with a two-year maturity and 1,666 common share purchase warrants. The debentures are convertible into common shares at $0.60 per share, while warrants are exercisable at $0.75 per share for two years. Interest payments will be made annually either in shares at the conversion price or in cash at the company's discretion.

Defence Therapeutics (OTCQB: DTCFF) has announced progress in its cancer therapy programs utilizing its proprietary Accum® technology in both Antibody Drug Conjugates (ADCs) and radiopharmaceuticals. The company's Accum®-based ADCs have shown enhanced efficacy in preclinical cancer models compared to conventional ADCs.

Defence is conducting studies through the Canadian Nuclear Laboratories under the CNRI-H program, focusing on biodistribution, pharmacokinetic profiles, and therapeutic potency. The company operates primarily from its Montreal laboratory while planning U.S. expansion. The target markets show significant potential, with the global ADC market projected to reach $29.9 billion by 2034 (9.23% CAGR) and the radiopharmaceutical market expected to hit $16.87 billion by 2033 (9.9% CAGR).

Defence Therapeutics (DTCFF) has received USPTO Notice of Allowance for patent application 18/351,291 covering next-generation antibody-drug conjugate (ADC) technology. The patent, valid until 2043, includes composition-of-matter claims for therapeutically active ADCs and their use in treating diseases like cancer. The company's Accum-based ADCs have shown enhanced intracellular delivery and cytotoxic activity in preclinical cancer models compared to conventional ADCs. The technology features antibodies conjugated to innovative constructs with bile acid and nuclear localization signal from RPS17. This adds to Defence's existing patent portfolio, which includes granted patents in the US, Japan, Australia, and Israel, marking their eighth U.S. patent overall.

Defence Therapeutics (DTCFF) has announced the opening of its first U.S. laboratory in the Boston-Cambridge biotech hub, specifically at Cambridge Scientific Labs in Watertown. This strategic expansion represents Defence's initial physical presence in the United States and will focus on developing and optimizing its proprietary Accum® technology for antibody-drug conjugates (ADCs). The company plans to use this location as a temporary base while exploring options for a permanent facility in the area. The move positions Defence within one of the world's leading biotech clusters, providing access to top scientific resources and collaboration opportunities.

Defence Therapeutics (OTCQB: DTCFF) has announced its participation in the BIO International Convention in Boston from June 16-19, 2025. The company's CEO and COO will attend this prestigious event, which attracts over 20,000 industry leaders worldwide. At the convention, Defence will showcase its Accum® technology, designed to enhance antibody-drug conjugates (ADCs) efficacy and improve tumor-killing capabilities.

The BIO International Convention serves as a vital platform for networking, fostering collaborations, and exploring investment opportunities in the biotechnology sector. Defence aims to leverage this event to advance discussions with potential partners and investors, supporting its mission to develop next-generation cancer therapies.

Defence Therapeutics (DTCFF) has announced a collaboration with Canadian Nuclear Laboratories (CNL) to enhance cancer treatments using a combination of Actinium-225 (Ac-225) and Defence's proprietary Accum® technology. The partnership aims to improve the delivery and efficacy of radio-immunoconjugate therapies.

The collaboration will focus on preclinical studies where CNL will evaluate tumor-targeting antibodies modified with Accum® technology to transport Ac-225. The research will assess biodistribution, therapeutic potency, and safety profiles in rodent models. Accum® technology is designed to enhance the escape of Ac-225-antibody complexes from cellular endosomes, potentially improving their nuclear accumulation while reducing required dosage levels and side effects.

CNL will produce and supply Ac-225 from its Th-229/Ac-225 generator at Chalk River Laboratories. This initiative aligns with the growing radiopharmaceutical market, projected to reach USD 16.87 billion by 2033.